Category - Markets

William Blair has launched coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $30 price target. The stock closed at $14.38 on Friday. Aclaris’ lead program, A-101, is a topical solution being...

H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of CASI Pharmaceuticals (NASDAQ:CASI) with a “buy” rating and $3 price target. The stock closed at $1.21 on Wednesday. CASI is a clinical-stage company...

Maxim Group has initiated coverage of Rock Creek Pharmaceuticals (NASDAQ:RCPI) with a “buy” rating and 12-month price target of $4. The stock closed at 83 cents on Monday. Rock Creek’s lead product, anatabine citrate...

Feltl & Co. has launched coverage of Viking Therapeutics (NASDAQ:VKTX) with a “strong buy” rating and price target of $17.50. The stock closed at $6.90 on Wednesday. “We anticipate the company executing on multiple...

H.C. Wainwright has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and $3 price target. The stock closed at $1.22 on Tuesday. Australia-based Prima is developing novel checkpoint modulators (CPMs)...

Titan Pharmaceuticals (OTCQB:TTNPD) has received approval to list its common stock on the NASDAQ Capital Market, effective at the opening on Monday, Oct.12, under the symbol TTNP. “Uplisting to the NASDAQ Capital Market...

Roth Capital Partners has initiated coverage of Immune Pharmaceuticals (NASDAQ:IMNP) with a “buy” rating and $6 price target. The stock closed at $1.21 on Wednesday. Immune is developing bertilimumab in combating...

Wedbush Securities has initiated coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with an “outperform” rating and 12-month price target of $15. The stock closed at $11.29 on Wednesday. Novadaq’s flagship SPY...

Rodman & Renshaw has initiated coverage of Evoke Pharma (NASDAQ:EVOK) with a “buy” rating and $27 price target. The stock closed at $2.91 on Wednesday. Evoke is currently focused on advancing an intranasal...

Rodman & Renshaw has launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMD) with a “buy” rating and $24 price target. The stock closed at $5.47 on Wednesday. “Oramed constitutes a differentiated take on diabetes...